JZP258 clinical trials
Also written JZP-258.
How each study uses JZP258 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JZP258 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
Jazz Pharmaceuticals (6) · Leiden University Medical Center (2) · Mayo Clinic (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test JZP258.
- Jan 2027Low Sodium Oxybate in Patients With Idiopathic HypersomniaPhase 4 · Mayo Clinic
- Sep 2027Stimulating Amyloid Clearance in Cerebral Amyloid AngiopathyPhase 2 · Leiden University Medical Center
Studies
Open first, then newest update. How each study uses JZP258 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHRecruitingPhase 3Jazz PharmaceuticalsNCT07625280Written as Xywav
- Efficacy, Safety and Tolerability of Low Sodium Oxybate for Nocturnal Cluster Headache AttacksNot yet recruitingPhase 2Leiden University Medical CenterNCT06950281Written as Low Sodium Oxybate
- Low Sodium Oxybate in Patients With Idiopathic HypersomniaRecruitingPhase 4Mayo ClinicNCT05837091Written as Low Sodium Oxybate
- Stimulating Amyloid Clearance in Cerebral Amyloid AngiopathyEnrolling by invitationPhase 2Leiden University Medical CenterNCT06421532Written as XYWAV
- A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or NarcolepsyCompletedPhase 4Jazz PharmaceuticalsNCT05875974Written as JZP258 (XYWAV)
- A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With NarcolepsyCompletedPhase 4Jazz PharmaceuticalsNCT05869773Written as JZP258
- An Interventional Safety Switch Study (Segue Study) of XYWAV in NarcolepsyCompletedPhase 4Jazz PharmaceuticalsNCT04794491Written as JZP-258
- A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety ExtensionCompletedPhase 3Jazz PharmaceuticalsNCT03533114Written as JZP-258
- A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With CataplexyCompletedPhase 3Jazz PharmaceuticalsNCT03030599Written as JZP-258